This from announce 12/2/17
The proposed study will investigate the efficacy, safety, and mechanism of action of ATL1102 dosed 200mg once weekly for 24 weeks in 16 relapsing SP-MS patients. This study would be expected to generate important and supportive data on the use of ATL1102 in this patient population and allow for the potential Early Access Program (EAP) treatment of patients who do not adequately respond to or tolerate existing therapies.
So KP EAP still on ...
Ann: Market and Technology Update, page-132
-
- There are more pages in this discussion • 27 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
